Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Ovid Therapeutics (OVID) Shares Issued (2017 - 2026)

Ovid Therapeutics filings provide 10 years of Shares Issued readings, the most recent being $2.4 million for Q1 2026.

  • Quarterly Shares Issued rose 18100.0% to $2.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Mar 2026, up 500.49% year-over-year, with the annual reading at $91000.0 for FY2025, 85.37% down from the prior year.
  • Shares Issued hit $2.4 million in Q1 2026 for Ovid Therapeutics, up from $63000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $2.4 million in Q1 2026 and bottomed at -$43599.0 in Q4 2022.
  • Average Shares Issued over 5 years is $252977.2, with a median of $67000.0 recorded in 2023.
  • The largest annual shift saw Shares Issued tumbled 106.05% in 2022 before it surged 18100.0% in 2026.
  • Ovid Therapeutics' Shares Issued stood at -$43599.0 in 2022, then soared by 175.69% to $33000.0 in 2023, then increased by 15.15% to $38000.0 in 2024, then surged by 65.79% to $63000.0 in 2025, then soared by 3655.56% to $2.4 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Shares Issued are $2.4 million (Q1 2026), $63000.0 (Q4 2025), and $15000.0 (Q3 2025).